VALN - Valneva SE

NasdaqGS - NasdaqGS Real-time price. Currency in USD
13.03
+0.42 (+3.30%)
As of 12:11PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close12.61
Open12.80
Bid12.83 x 1200
Ask13.20 x 800
Day's range12.66 - 13.03
52-week range9.07 - 33.76
Volume19,043
Avg. volume7,800
Market cap900.265M
Beta (5Y monthly)0.96
PE ratio (TTM)N/A
EPS (TTM)-2.68
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est18.89
  • Globe Newswire

    Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

    Saint-Herblain (France), May 31, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will attend the Jefferies Healthcare Conference (June 7-9 in New York), Goldman Sachs Annual Global Healthcare Conference (June 12-15 in Dana Point, California) and the Stifel European Healthcare Conference (June 28-30 in Bordeaux, France). Valneva will present and meet with institutional investors to discuss the Company’s late-stage vacc

  • Globe Newswire

    Valneva Announces the Availability of Documentation for its Shareholder Meeting

    Saint-Herblain (France), May 31, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the availability of documentation for its Combined General Meeting to be held on June 21, 2023 at 2 p.m. CEST, at the hotel InterContinental Lyon – Hotel Dieu, 20 Quai Jules Courmont, 69002 Lyon (France). The preliminary Notice of Meeting, containing the agenda, the draft resolutions and instructions for participation and voting, was published in the French Bulleti

  • Zacks

    Valneva (VALN) Stock Down 53% in the Past Year: Here's Why

    The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.

  • Globe Newswire

    Valneva Files for Chikungunya Vaccine Authorization with Health Canada

    Saint-Herblain (France), May 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the filing of a regulatory application with Health Canada for marketing approval of the Company’s single-shot chikungunya vaccine candidate, VLA1553, in persons aged 18 years and above. If accepted, Health Canada will provide additional information on the potential approval timeline. This is the second regulatory application for VLA1553 filed by Valneva, and the Co

  • Globe Newswire

    VALNEVA - Declaration of shares and voting rights - April 30, 2023

    VALNEVA Declaration of shares and voting rightsApril 30, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: May 4, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change was rec

  • Globe Newswire

    Valneva Reports First Quarter 2023 Financial Results and Provides Corporate Updates

    Product sales increased 98.6% to €32.1 million in the first quarter of 2023 compared to €16.2 million in the first quarter of 2022 Driven by IXIARO® and DUKORAL® sales both of which more than quadrupled year-over-yearTotal revenues of €33.5 million in the first quarter of 2023 compared to €21.8 million in the first quarter of 2022 Strong cash position of €254.5 million at March 31, 2023 Chikungunya: progressing towards delivery of the world’s first chikungunya vaccine Prescription Drug User Fee

  • Globe Newswire

    VALNEVA - Declaration of shares and voting rights - March 31, 2023

    VALNEVA Declaration of shares and voting rightsMarch 31, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: April 6, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change was r

  • Globe Newswire

    Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F

    Saint-Herblain (France), March 31, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 30 2023, of its 2022 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.23-0199 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC). Valneva’s 2022 Universal Registration Document includes the Company’s 2022 audited Annual Financial Report, the Management Boar

  • Globe Newswire

    Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.

    Saint Herblain (France), March 30, 2023 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today it will present on its single-shot chikungunya vaccine candidate, VLA1553, and host a roundtable on Zika vaccines next week at the 23rd World Vaccine Congress in Washington, D.C. On April 4, 2023, at 11.40am EDT, Valneva’s Chief Medical Officer, Juan Carlos Jaramillo, MD, will host a roundtable discussion on the opportunities and challenges for a Zika vaccine. Val

  • Globe Newswire

    Valneva Reports Full Year 2022 Results and Provides Corporate Updates

    Total revenues of €361.3 million in 2022 compared to €348.1 million in 2021 Driven by product sales of €114.8 million (82.3% increase compared to 2021), including €85.2 million of travel vaccine sales and €29.6 million of COVID-19 vaccine sales€246.5 million of Other Revenues, primarily driven by revenue recognition related to previous COVID-19 vaccine supply agreements Strong cash position of €289.4 million at December 31, 2022 Raised over €190 million in equity: €102.9 million of gross proceed

  • Globe Newswire

    VALNEVA - Declaration of shares and voting rights - February 28, 2023

    VALNEVA Declaration of shares and voting rightsFebruary 28, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: March 6, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change wa

  • Globe Newswire

    Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001

    Saint-Herblain (France), March 2, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated COVID-19 vaccine, VLA2001. As previously announced, Valneva will not invest in further development of the vaccine, in the absence of a new partnership1. It is, however, completing remaining clinical studies and submissions as agreed with regulators. On Febru

  • Globe Newswire

    Valneva to Present at the Cowen 43rd Annual Healthcare Conference

    Saint-Herblain (France), March 1, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Cowen 43rd Annual Healthcare Conference, to take place in-person March 6 - 8, 2023 in Boston, Massachusetts. Key topics to be covered by Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler include the Company’s late-stage va

  • Globe Newswire

    FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review

    Saint-Herblain (France), February 20, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Administration (FDA) has completed a filing review of its Biologics License Application for Valneva’s single-shot chikungunya vaccine candidate VLA1553 and has determined that the application is sufficiently complete to permit a substantive review. The review classification is Priority. VLA1553 has been assigned a Prescription Drug

  • Globe Newswire

    Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

    New York & Saint-Herblain (France), February 17, 2023 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announce that Pfizer, as the study sponsor, has decided to discontinue a significant percentage of participants in the U.S. who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) Phase 3 clinical study. The study is investigating the efficacy, safety and immunogenicity of an investigational Lyme disease vaccine candid

  • Globe Newswire

    Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 Guidance

    Total revenues of €361.3 million in 2022 were ahead of previously communicated guidance of €340 million to €360 million1 (compared to €348.1 million in 2021) Driven by Product Sales of €114.8 million (82.3% increase compared to 2021), including €85.2 million of travel vaccine sales and €29.6 million of COVID-19 vaccine sales€246.5 million of Other Revenues mainly driven by revenue recognition related to previous COVID-19 vaccine supply agreements Strong cash position of €289.4 million at Decembe

  • Globe Newswire

    Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

    Saint-Herblain (France), February 14, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it completed enrollment and vaccination for a Phase 3 trial in adolescents, VLA1553-321, of its single-shot chikungunya vaccine candidate, VLA1553. First results of the trial are expected mid-2023. Funded by the Coalition for Epidemic Preparedness Innovations (CEPI), the VLA1553-321 adolescent trial is intended to support the label extension in this age g

  • Globe Newswire

    VALNEVA Declaration of shares and voting rights - January 31, 2023

    VALNEVA Declaration of shares and voting rightsJanuary 31, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment A Declaration date: February 3, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change

  • Globe Newswire

    VALNEVA - Declaration of shares and voting rights: Status on December 31, 2022 (corrected data) and January 4, 2023

    VALNEVA Declaration of shares and voting rightsStatus on December 31, 2022 (corrected data) and January 4, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment A Declaration date: January 19, 2023 Erratum: status on December 31, 2022 Number of shares composing the share capital of ValnevaTotal number of voting rights

  • Zacks

    Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why

    Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.

  • Globe Newswire

    VALNEVA - Declaration of shares and voting rights: December 31, 2022

    VALNEVA Declaration of shares and voting rightsDecember 31, 2022 __________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment A Declaration date: January 5, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change

  • Zacks

    What Makes Valneva SE Sponsored ADR (VALN) a New Buy Stock

    Valneva SE Sponsored ADR (VALN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • Globe Newswire

    Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine

    Saint-Herblain (France), December 30, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001. In study VLA2001-3071, a subset of participants (three out of nine groups) received VLA2001 following two or three doses of mRNA COVID-19 vaccine, with or without break-through infection (25-50 participants per group). The data show that a

  • Investing.com

    Tesla, Meta Platforms, and Valneva rise premarket

    By Peter Nurse

  • Globe Newswire

    Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate

    Saint-Herblain (France), December 23, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that it has completed rolling submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its single-shot chikungunya vaccine candidate, VLA1553. Valneva is seeking approval of its investigational chikungunya vaccine in persons aged 18 years and above. This BLA application follows final pivotal Phase 3 data reported